IJR News — today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Ask Genius
Apps
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars
Brands
Yourlist
Quizie
F
FaithTap
B
Blessed
All brands
Ask Genius
Apps
Trending
📊 Approval movers
Gordon Liu
100%
Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial
x/nanobiotix
— 5d
Nanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.
+3
2
Share
Sam Okafor
The fact that it works with lower re-irradiation doses could mean fewer side effects for patients facing this again.
